Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥258.72 million, representing a 6.79% increase compared to ¥242.27 million in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2022 was approximately ¥21.47 million, an increase of 27.30% from ¥16.87 million in the previous year[19]. - The basic earnings per share for the first half of 2022 was ¥0.0575, up 27.21% from ¥0.0452 in the same period last year[19]. - The net cash flow from operating activities for the first half of 2022 was approximately ¥24.25 million, a significant recovery from a negative cash flow of ¥27.73 million in the previous year[19]. - The total assets at the end of the reporting period were approximately ¥1.87 billion, showing a slight increase of 0.14% from ¥1.87 billion at the end of the previous year[19]. - The company's net assets attributable to shareholders at the end of the reporting period were approximately ¥1.68 billion, reflecting a 1.30% increase from ¥1.66 billion at the end of the previous year[19]. - The weighted average return on net assets for the first half of 2022 was 1.29%, an increase of 0.31 percentage points compared to 0.98% in the same period last year[19]. - The net profit after deducting non-recurring gains and losses was 20.09 million yuan, up 42.26% year-on-year[29]. - The company achieved operating revenue of 258.72 million yuan, an increase of 6.79% year-on-year, with the pharmaceutical industry contributing 251.04 million yuan, up 8.70% year-on-year[29]. Market Position and Industry Context - As of June 2022, the pharmaceutical manufacturing industry in China generated a total revenue of 1,400.78 billion yuan, a slight decrease of 0.6% year-on-year, with total profits dropping by 27.6% to 220.95 billion yuan[23]. - The company’s main product, Jintian Ge Capsule, is recognized as a first-class new drug and has become a leading medication in orthopedic clinical applications[26]. - The company is positioned in the pharmaceutical manufacturing industry, focusing on the research, production, and sales of various drug types, including chemical drugs and traditional Chinese medicine[26]. - The company’s core products have been included in 35 authoritative clinical guidelines, reinforcing its leading position in the orthopedic traditional Chinese medicine sector[31]. - The company is benefiting from favorable policies supporting the development of traditional Chinese medicine, which is expected to drive rapid growth in the industry[25]. - The pharmaceutical market demand is projected to continue growing due to an aging population and increasing chronic disease prevalence[24]. - The company has been recognized in the "2021 Annual Top 100 Chinese Pharmaceutical Industry" list, further solidifying its market position[31]. Research and Development - Research and development expenses decreased by 53.53% to 3.96 million yuan due to pandemic-related impacts on certain projects[44]. - The company emphasized the development of new products and technologies, increasing R&D investment and collaboration with external research institutions[39]. - The company has not disclosed any new product or technology developments in the current reporting period[78]. Environmental and Social Responsibility - The company has not faced any significant environmental issues or administrative penalties related to environmental pollution during the reporting period[68]. - The wastewater treatment capacity is 10m³/h (240m³/d), and the treated wastewater meets the discharge standards[68]. - The concentration of nitrogen oxides from the natural gas boiler after low-nitrogen transformation is 50mg/m³, complying with the emission limit of 80mg/m³[69]. - The company has implemented a comprehensive environmental monitoring plan, ensuring all pollutants are within the discharge standards[70]. - The company has adopted various measures to reduce carbon emissions, including energy-saving practices and the use of clean energy sources[73]. - The company promotes a low-carbon lifestyle among employees, encouraging energy conservation and waste reduction initiatives[74]. Financial Management and Investments - The company acquired 100% equity of Xi'an Jishitang Pharmaceutical Co., Ltd. for CNY 289,800[49]. - The company plans to develop a new product research and exhibition center in Changning New District, with a property purchase of CNY 98,000,000[50]. - The company reported a total of 1,486,296.83 RMB in related party transactions during the reporting period, with significant transactions including 747,125.60 RMB for property leasing[81]. - The company has a judicial freeze on CNY 54,046,425.80 in assets due to a legal dispute[48]. - The company is in the process of transferring 100% equity of Jin Hua International Hotel Co., Ltd., with an assessed value of CNY 368,938,800[51]. Shareholder and Corporate Governance - The total number of ordinary shareholders as of the end of the reporting period is 20,179[87]. - The largest shareholder, Xing Boyue, holds 68,881,152 shares, representing 18.45% of the total shares[89]. - The second-largest shareholder, Xinyu Xingpeng Tongchuang Enterprise Management Partnership, holds 33,448,827 shares, representing 8.96%[89]. - The company has no plans for profit distribution or capital reserve transfer for the half-year period[63]. - The employee stock ownership plan has been extended for an additional 12 months, now set to expire on March 27, 2023, with 644,700 shares sold and 644,859 shares remaining unsold[65]. Legal and Compliance Issues - The company faced 245 lawsuits related to securities false statements, with 12 cases withdrawn and 182 cases settled by the reporting date[79]. - There were no major litigation or arbitration matters reported during the period[80]. - The company has not reported any violations or penalties involving its directors, supervisors, or senior management during the reporting period[80]. Accounting and Financial Reporting - The financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance[137]. - The company conducts impairment tests on long-term assets, including fixed assets and intangible assets, at each balance sheet date[192]. - If the recoverable amount of an asset is less than its carrying amount, an impairment loss is recognized, which cannot be reversed in future periods[193]. - The company recognizes provisions for liabilities when obligations meet specific criteria, including current obligations likely to result in economic outflows[200].

Financial Performance - In 2021, the company's operating revenue was CNY 534,036,500.95, a decrease of 20.08% compared to CNY 668,180,334.76 in 2020[22] - The net profit attributable to shareholders of the listed company for 2021 was CNY -18,160,452.12, representing a decline of 148.12% from CNY 37,738,016.78 in 2020[22] - The net cash flow from operating activities was CNY 30,594,673.93, down 34.29% from CNY 46,558,370.18 in the previous year[22] - The total assets at the end of 2021 were CNY 1,870,188,073.55, a decrease of 4.51% from CNY 1,958,574,300.85 at the end of 2020[22] - The net assets attributable to shareholders of the listed company decreased by 3.78% to CNY 1,656,217,718.69 at the end of 2021 from CNY 1,721,338,898.70 at the end of 2020[22] - The basic earnings per share for 2021 was CNY -0.0487, a decrease of 145.99% compared to CNY 0.1059 in 2020[23] - The weighted average return on net assets was -1.08% in 2021, a decrease of 3.28 percentage points from 2.20% in 2020[23] - The company reported a net profit of CNY 35,853,424.89 after deducting non-recurring gains and losses, an increase of 38.31% from CNY 25,922,513.13 in 2020[22] - The net profit attributable to the parent company for the year was -18.16 million RMB, with a significant loss of -41.18 million RMB in Q4, contrasting with profits in the first three quarters[26] - The net profit after deducting non-recurring gains and losses was 35.85 million RMB for the year, with quarterly figures of 4.91 million, 9.21 million, 11.45 million, and 10.28 million RMB[26] Revenue and Sales - The company's total revenue for the year was 534.04 million RMB, with quarterly revenues of 106.80 million, 135.46 million, 148.76 million, and 143.01 million RMB respectively[26] - The pharmaceutical manufacturing segment generated sales revenue of CNY 512.47 million, down 12.82% year-on-year, primarily due to reduced sales volume impacted by the pandemic[52] - The orthopedic product sales revenue was CNY 394.89 million, a decrease of 16.95% year-on-year, with a gross margin of 87.32%[56] - The hotel segment reported operating revenue of CNY 21.85 million, an increase of 6.97% year-on-year[52] - The online pharmacy sales scale grew by 61% year-on-year in the first half of 2021, becoming an important sales channel for pharmaceuticals[38] Research and Development - R&D efforts are concentrated on core products, including process improvements and expanding indications, while also collaborating with external research institutions to enhance competitiveness[35] - The total R&D expenditure amounted to 22,484,077.16, which is 4.21% of operating revenue, with capitalized R&D accounting for 30.37% of total R&D[66] - The company is focusing on secondary development of core products and the development of new health food products, enhancing its R&D capabilities through both internal and external collaborations[97] - Key ongoing R&D projects include clinical studies for Jin Tiange and the TF series products aimed at enhancing immunity[99] - The company has completed the clinical research for Jin Tiange aimed at osteoporosis and osteoarthritis, while other projects are in various stages of research and evaluation[99] Marketing and Strategy - The company has focused on enhancing its marketing strategy, leveraging online platforms to increase brand awareness and market share in the bone and muscle health sector[34] - The company’s marketing network covers the entire country, supported by a professional academic promotion team[49] - The company is enhancing its marketing framework through academic promotion, brand building, and market research to improve sales performance[104] - The company is actively pursuing mergers and acquisitions to extend its product line and enhance its market position[114] Corporate Governance - The governance structure is robust, ensuring compliance with regulations and protecting the interests of all shareholders[123] - The company has independent directors, including Shi Ping, who received 10.00 million yuan in pre-tax compensation[128] - The company has a diverse board with members aged between 26 and 73, ensuring a range of perspectives[128] - The company has appointed new independent directors, including Yike and Zhao Ge, to strengthen its governance structure[130] - The company is actively engaging in corporate governance reforms to improve operational efficiency and accountability[130] Environmental and Social Responsibility - The company is committed to environmental protection, continuously improving its environmental management systems and reducing emissions from production sources[173] - The company engages in various charitable activities, demonstrating its commitment to corporate social responsibility[173] - The company actively promotes low-carbon initiatives, including energy-saving measures and waste reduction strategies, contributing to national carbon neutrality goals[169] - The company has established a comprehensive environmental monitoring plan, with third-party assessments confirming that all monitored pollutants meet the required standards[168] Financial Management - The company has bank entrusted wealth management with a total amount of 11,378.59 million yuan from self-owned funds and 40,000 million yuan from raised funds[185] - The company has a total of 13,533 million yuan in unexpired balances from bank entrusted wealth management[185] - The company has consistently achieved returns above 15% on various financial products, showcasing effective asset management[187][188][189][190] - The company has a plan for future investments in financial products, indicating ongoing financial strategy development[187][188][189][190] Challenges and Risks - The company is facing industry policy risks due to regulatory changes, which may lead to increased competition and challenges in the pharmaceutical sector[118] - Rising costs of raw materials and labor, along with price control measures, pose significant pressure on the company's profit growth[118] - To address risks, the company is enhancing market price monitoring and optimizing product structure while increasing investment in R&D projects[121] Employee Training and Development - The training program aims for a coverage rate of 100% for all employees, with a course opening rate of over 90%[149] - The company emphasizes the importance of internal training, with at least 70% of training sessions conducted by management and technical personnel[148] - Each employee is required to complete a minimum of 14 hours of training per year, with specific assessment criteria based on their job level[149] - The company has established a three-tier training system within the production department, focusing on GMP standards, quality regulations, and team building[150]

Financial Performance - The company's operating revenue for Q1 2022 was ¥119,199,841.13, representing an increase of 11.61% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2022 was ¥9,280,142.36, reflecting a growth of 22.92% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥11,893,928.31, showing a significant increase of 142.05% compared to the previous year[5] - Total revenue for Q1 2022 reached ¥119,199,841.13, an increase of 11.3% compared to ¥106,800,468.41 in Q1 2021[20] - Operating profit for Q1 2022 was ¥10,554,347.18, a decrease of 9.3% from ¥11,634,905.16 in Q1 2021[21] - Net profit for Q1 2022 was ¥9,280,142.36, up 23.0% from ¥7,549,682.33 in Q1 2021[21] - The total comprehensive income for Q1 2022 was CNY 9,280,142.36, an increase from CNY 7,549,682.33 in Q1 2021, reflecting a growth of approximately 23%[22] - The basic earnings per share for Q1 2022 was CNY 0.0249, up from CNY 0.0236 in Q1 2021, marking an increase of about 5.5%[22] - The net profit for Q1 2022 reached CNY 15,885,298.87, a significant increase of 191.5% from CNY 5,449,467.42 in Q1 2021[31] Assets and Liabilities - Total assets at the end of Q1 2022 were ¥1,865,565,960.59, a slight decrease of 0.25% from the end of the previous year[6] - Total current assets decreased to ¥713,008,346.32 from ¥852,633,045.92 at the end of 2021, representing a decline of 16.4%[15] - Total non-current assets increased to ¥1,152,557,614.27 from ¥1,017,555,027.63, marking a growth of 13.2%[15] - Total liabilities decreased to ¥200,068,099.54 from ¥213,970,354.86, a reduction of 6.5%[16] - The total assets of the company as of March 31, 2022, were CNY 1,843,755,335.46, slightly up from CNY 1,843,031,565.31 at the end of 2021[28] - The total liabilities of the company decreased to CNY 179,530,793.43 as of March 31, 2022, down from CNY 194,692,322.15 at the end of 2021, reflecting a reduction of approximately 7.8%[28] Cash Flow - The net cash flow from operating activities for Q1 2022 was ¥13,070,625.82, with no applicable percentage change reported[5] - In Q1 2022, the company reported a net cash flow from operating activities of CNY 13,070,625.82, a significant improvement from a net outflow of CNY 37,984,546.27 in Q1 2021[25] - The cash flow from operating activities generated a net cash inflow of CNY 13,920,639.84, compared to a net outflow of CNY 35,939,908.41 in Q1 2021[34] - The company achieved a net cash flow from investment activities of CNY 62,615,259.10 in Q1 2022, compared to CNY 13,544,688.18 in Q1 2021, indicating a positive trend in investment returns[25] - The company reported a total cash inflow from investment activities of CNY 670,486,080.38 in Q1 2022, a significant increase from CNY 164,456,734.60 in Q1 2021[25] - The company’s cash flow from financing activities showed a net outflow of CNY 157,679.45 in Q1 2022, an improvement from a net outflow of CNY 812,500.00 in Q1 2021[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 21,803[9] - The top shareholder, Xing Boyue, held 17.30% of the shares, amounting to 64,566,652 shares[9] - The company's total equity attributable to shareholders was ¥1,665,497,861.05, which increased by 0.56% compared to the end of the previous year[6] - The total equity increased to CNY 1,664,224,542.03 from CNY 1,648,339,243.16, reflecting a growth in shareholder value[29] Research and Development - Research and development expenses for Q1 2022 were ¥1,632,054.20, down from ¥4,239,012.90 in Q1 2021, indicating a reduction of 61.5%[20] - Research and development expenses decreased to CNY 1,632,054.20 from CNY 4,239,012.90, indicating a strategic shift in R&D investment[30] Investment Income - The company reported a significant increase in investment income to ¥12,095,333.71 in Q1 2022, compared to ¥6,391,089.19 in Q1 2021[21] - The company reported a significant increase in investment income, totaling CNY 12,095,333.71, up from CNY 6,391,089.19 in the same period last year[30] Cash and Cash Equivalents - The company’s cash and cash equivalents increased to ¥191,330,886.39 from ¥160,802,837.08, reflecting a growth of 19.0%[14] - The company's cash and cash equivalents at the end of Q1 2022 stood at CNY 191,330,886.39, compared to CNY 344,701,160.17 at the end of Q1 2021, indicating a decrease of approximately 44.5%[26] - The company recorded a cash and cash equivalents balance of CNY 190,334,087.60 at the end of Q1 2022, compared to CNY 338,422,820.25 at the end of Q1 2021[34] Financial Expenses - The company’s financial expenses showed a significant reduction, with interest expenses at CNY 157,679.45 compared to CNY 812,500.00 in the previous year[30]

Financial Performance - In 2021, the company's operating revenue was CNY 534,036,500.95, a decrease of 20.08% compared to CNY 668,180,334.76 in 2020[22] - The net profit attributable to shareholders of the listed company for 2021 was CNY -18,160,452.12, a decline of 148.12% from CNY 37,738,016.78 in 2020[22] - The net cash flow from operating activities was CNY 30,594,673.93, down 34.29% from CNY 46,558,370.18 in 2020[22] - As of the end of 2021, the total assets amounted to CNY 1,870,188,073.55, a decrease of 4.51% from CNY 1,958,574,300.85 at the end of 2020[22] - The net assets attributable to shareholders of the listed company were CNY 1,656,217,718.69, a decrease of 3.78% from CNY 1,721,338,898.70 in 2020[22] - The basic earnings per share for 2021 was CNY -0.0487, a decline of 145.99% compared to CNY 0.1059 in 2020[23] - The weighted average return on net assets was -1.08% in 2021, a decrease of 3.28 percentage points from 2.20% in 2020[23] - The company plans not to distribute profits for 2021 due to a negative net profit attributable to shareholders[6] Revenue Breakdown - The company's total revenue for the year was 534.04 million RMB, with quarterly revenues of 106.80 million, 135.46 million, 148.76 million, and 143.01 million RMB respectively[26] - The net profit attributable to the parent company for the year was -18.16 million RMB, with quarterly figures of 0.75 million, 0.93 million, 0.62 million, and -4.12 million RMB[26] - The net profit after deducting non-recurring gains and losses for the year was 35.85 million RMB, with quarterly figures of 0.49 million, 0.92 million, 1.15 million, and 1.03 million RMB[26] - The company reported a significant decline in net profit in Q4, primarily due to provisions for litigation losses[26] Market and Industry Insights - In 2021, the pharmaceutical manufacturing industry achieved a revenue of CNY 2,928.85 billion, representing a year-on-year growth of 20.1%[38] - The total sales revenue of the hospital market reached CNY 988.3 billion, with a year-on-year increase of 10.1%[38] - The profit of large-scale pharmaceutical industrial enterprises totaled CNY 627.14 billion, an increase of 77.9% compared to the previous year[38] - The online pharmacy sales scale grew by 61% year-on-year in the first half of 2021, becoming an important sales channel for pharmaceuticals[38] Product and R&D Focus - The company’s main product, Jintian Ge Capsule, is recognized as a first-class new drug and has established a leading position in the orthopedic clinical market[44] - R&D efforts are concentrated on improving existing core products and collaborating with external research institutions to enhance competitiveness[35] - The company has been actively increasing R&D investment, focusing on high-standard post-marketing research projects to support its brand strategy[89] - Key ongoing R&D projects include clinical studies for Jin Tiange and the TF series products aimed at enhancing immunity[99] Cost Management and Efficiency - The gross profit margin for the pharmaceutical manufacturing segment was 77.19%, a decrease of 2.19 percentage points compared to the previous year[54] - The total cost of goods sold decreased by 15.07% to 379,759,375.49, indicating improved cost management[65] - The company reduced sales expenses by 14.24% to 315,056,505.52 and management expenses by 27.73% to 49,722,190.26 compared to the previous period[65] Cash Flow and Investments - The company’s cash flow from operating activities was CNY 30.59 million, down 34.29% year-on-year due to reduced sales collections[54] - The company’s investment activities resulted in a net cash outflow of CNY 152.90 million, primarily due to significant expenditures on financial products[54] - The net cash flow from financing activities also turned negative at CNY -86,844,325.63, mainly due to repayment of bank loans and dividend distributions[70] Governance and Management - The company’s governance structure complies with relevant regulations, with no significant differences noted[126] - The company has independent directors, including Shi Ping, who received 10 million yuan in remuneration, and Zhao Ge and Yi Ke, whose remuneration details were not disclosed[128] - The company has a structured approach to maintaining independence from its controlling shareholders and actual controllers[126] - The company’s management team includes experienced individuals, with the general manager, Han Zhuojun, receiving 73.60 million yuan in remuneration[128] Environmental Responsibility - The company has not faced any significant environmental issues or administrative penalties related to environmental protection during the reporting period[163] - The company’s wastewater treatment facility has a processing capacity of 10m³/h (240m³/d), ensuring compliance with discharge standards[163] - The company actively promotes low-carbon initiatives, including energy-saving measures and waste reduction strategies, contributing to national carbon neutrality goals[170] Employee Development and Training - The company has established a three-tier training system within the production department, ensuring regular training sessions for all levels of staff[150] - The training program aims for a coverage rate of 100% for all employees, with a course opening rate of over 90%[149] - Each employee is required to complete a minimum of 14 hours of training per year, with specific assessment criteria based on their job level[149] Strategic Initiatives - The company plans to expand its market presence and enhance product offerings through strategic acquisitions and partnerships[130] - The company is focusing on new product development and technological advancements to drive future growth[130] - The company has set ambitious performance guidance for the upcoming fiscal year, aiming for a revenue growth of 10%[130]

金花企业（集团）股份有限公司 2021 年第三季度报告 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 证券代码：600080 证券简称：金花股份 金花企业（集团）股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 | 项目 | 本报告期 | 本报告期比上 年同期增减变 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 动幅度(%) | | 增减变动幅度 | | | | | | (%) | | 营业收入 | 148,756,473.00 | -23.84 | 391, ...

Financial Performance - The company's operating revenue for the first half of 2021 was approximately ¥242.27 million, a decrease of 6.87% compared to ¥260.13 million in the same period last year[23]. - The net profit attributable to shareholders for the first half of 2021 was approximately ¥16.87 million, representing an increase of 16.98% from ¥14.42 million in the previous year[23]. - The basic earnings per share for the first half of 2021 was ¥0.0452, up 17.10% from ¥0.0386 in the same period last year[22]. - The net profit after deducting non-recurring gains and losses was approximately ¥14.12 million, a significant increase of 74.92% compared to ¥8.07 million in the previous year[23]. - The total assets at the end of the reporting period were approximately ¥1.88 billion, down 4.08% from ¥1.96 billion at the end of the previous year[23]. - The net cash flow from operating activities for the first half of 2021 was negative at approximately -¥27.73 million, compared to -¥24.44 million in the same period last year[23]. - The company achieved operating revenue of 242.27 million yuan, a decrease of 6.87% compared to the same period last year, with the pharmaceutical industry contributing 230.94 million yuan, an increase of 2.46%[31]. - The net profit attributable to shareholders was 16.87 million yuan, an increase of 16.98% year-on-year, while the net profit after deducting non-recurring gains and losses was 14.12 million yuan, up 74.92%[31]. Research and Development - R&D expenses rose significantly by 173.74% to CNY 8.53 million, reflecting the company's commitment to innovation[43]. - The company is actively increasing R&D investment to develop new products and enhance its core competitiveness in the orthopedic field[34]. - Research and development expenses rose significantly to CNY 8,525,460.47, compared to CNY 3,114,476.91, indicating an increase of 173.5%[96]. - The company has initiated supplementary applications for already listed products, which are aimed at modifying or expanding the approved matters of new drugs, generics, or imported drugs, confirming intangible assets upon obtaining revised drug certificates or approval numbers from the National Medical Products Administration[178]. Market Position and Strategy - The company’s leading product, Jintian Ge Capsule, holds a market share of 38.96% in the osteoporosis medication category among top products in public hospitals in key cities, ranking first[32]. - The company has established a comprehensive marketing network covering the entire country, utilizing a professional academic promotion model to enhance product recognition and application in the medical field[35]. - The company is actively expanding its digital marketing strategy and enhancing its database for more precise promotional efforts[39]. - The company is focusing on strengthening core channels and expanding retail markets to drive performance growth[39]. - The company has been recognized for its brand strength, with its "Jinhua" trademark being acknowledged as a famous Chinese trademark, enhancing its market competitiveness[36]. Financial Position - The total number of shares and the capital structure of the company remained unchanged during the reporting period[77]. - The total number of ordinary shareholders at the end of the reporting period was 23,341[80]. - The largest shareholder, Jinhua Investment Holding Group Co., Ltd., held 71,447,654 shares, representing 19.14% of the total shares[82]. - The total equity attributable to shareholders was CNY 1,704,859,087.35, down from CNY 1,721,338,898.70, a decline of approximately 0.95%[89]. - The company reported a decrease in undistributed profits by CNY 33,594,325.65 during the same period[118]. Environmental and Quality Management - The company emphasizes strict quality control throughout the drug production process, adhering to the new Drug Administration Law and ensuring compliance with production quality management standards[52]. - The company has a wastewater treatment capacity of 240m³/d, utilizing an anaerobic and aerobic combined process to ensure compliance with wastewater discharge standards[60]. - The company’s nitrogen oxide emissions from its natural gas boiler are maintained below 80mg/m³ after low-nitrogen transformation, complying with environmental standards[60]. - The company actively promotes low-carbon initiatives, including energy-saving measures and waste reduction strategies, contributing to national carbon neutrality goals[66]. - The company has established a management system to monitor and respond to changes in pharmaceutical industry policies and regulations[52]. Risks and Legal Matters - The company reported no significant risks that could materially affect its operations during the reporting period[7]. - The company is navigating industry policy risks and cost pressures due to rising raw material prices and regulatory changes[50]. - The company faces multiple risks in drug development, including technological, financial, management, production, environmental, and market risks, characterized by high technology, high investment, high risk, and long cycles[51]. - The company is involved in ongoing litigation related to contract disputes, with a total amount involved of approximately 54.05 million yuan[72]. - The company is facing a securities false statement liability lawsuit with a total claim amount of approximately 7.05 million yuan[72]. Accounting and Financial Reporting - The financial statements are prepared based on the going concern assumption, indicating a stable operational history[126]. - The accounting policies are in accordance with the enterprise accounting standards, ensuring accurate financial reporting[128]. - Revenue is recognized when the company fulfills its performance obligations, with the transaction price allocated to each performance obligation based on their standalone selling prices[188]. - The company conducts impairment tests annually for goodwill and intangible assets with indefinite useful lives, ensuring compliance with accounting standards[179]. - The company recognizes expected credit losses for receivables based on historical loss experience and future economic forecasts[155].

Financial Performance - In 2020, the company's operating revenue was CNY 668,180,334.76, a decrease of 11.45% compared to CNY 754,544,013.66 in 2019[20] - The net profit attributable to shareholders was CNY 37,738,016.78, representing a 45.69% increase from CNY 25,902,673.81 in the previous year[20] - The net profit after deducting non-recurring gains and losses was CNY 25,922,513.13, up 93.67% from CNY 13,385,086.97 in 2019[20] - The basic earnings per share for 2020 was CNY 0.1059, an increase of 45.67% from CNY 0.0727 in 2019[21] - The total assets at the end of 2020 were CNY 1,958,574,300.85, a decrease of 1.07% from CNY 1,979,851,640.25 at the end of 2019[20] - The company's net cash flow from operating activities was CNY 46,558,370.18, down 58.22% from CNY 111,445,504.03 in 2019[20] - The weighted average return on equity increased to 2.20% in 2020, up from 1.49% in 2019, an increase of 0.71 percentage points[21] - The company reported a net asset attributable to shareholders of CNY 1,721,338,898.70 at the end of 2020, a slight increase of 0.37% from CNY 1,714,985,578.65 at the end of 2019[20] Dividend Distribution - The company plans to distribute a cash dividend of CNY 0.90 per 10 shares, totaling CNY 33,594,325.65, which accounts for 89.02% of the net profit attributable to shareholders[5] - The company declared a cash dividend of 0.30 RMB per 10 shares, totaling 11,198,108.55 RMB, which represents 43.23% of the net profit attributable to shareholders for the year 2019[121] - In 2020, the company distributed a cash dividend of 1.00 RMB per 10 shares, amounting to 33,594,325.65 RMB, which accounted for 89.02% of the net profit attributable to shareholders[123] Business Operations - The company exited the pharmaceutical distribution business in November 2020 to focus resources on pharmaceutical manufacturing[27] - The company's main business includes the R&D, production, and sales of various pharmaceutical products, including chemical drugs and traditional Chinese medicine[26] - The company plans to continue expanding its market presence and enhancing its product offerings in the pharmaceutical sector[26] - The company has focused on product development in the orthopedic, immunology, and pediatrics sectors, with its leading product, Jintian Ge capsules, gaining significant market recognition[39] - The company has implemented a marketing strategy that includes online courses and self-media platforms to enhance brand academic image and customer engagement during the pandemic[45] Research and Development - Research and development expenses increased by 10.46% to CNY 20.07 million, indicating a commitment to innovation despite overall revenue decline[53] - The company’s R&D investment for the reporting period was CNY 24.87 million, accounting for 3.72% of total revenue and 4.23% of parent company revenue[98] - The company plans to strengthen collaboration with external R&D institutions and increase R&D investment to meet future development needs[98] - The company has ongoing R&D projects aimed at improving quality standards and expanding indications for its core products[92] - The company has strengthened R&D investments and is conducting multiple high-standard post-marketing research projects, focusing on drug mechanisms and clinical efficacy[84] Market Position and Product Performance - The main product, Jintian Ge capsules, has established a competitive advantage in the orthopedic clinical market, contributing to stable revenue growth[26] - The orthopedic product line generated revenue of CNY 475.48 million, with a gross margin of 87.57%, despite an 8.80% decrease in revenue year-on-year[56] - The company's leading product, Jintian Ge capsules, holds a market share of 40.53% in the top ten traditional Chinese medicine products for osteoporosis in key urban public hospitals[84] - The immune category products, including Transfer Factor Capsule, reported revenue of ¥56.45 million, with a gross margin of 54.40%, reflecting a year-over-year increase of 10.15%[91] - The orthopedic product line accounted for 80.89% of the company's total pharmaceutical revenue, indicating strong market profitability[91] Financial Management and Investments - The company has engaged in multiple entrusted financial management projects with various banks, with expected annualized returns ranging from 1.12% to 8.14%[144] - The company has no plans for impairment provisions related to entrusted financial management[144] - The company has entrusted cash asset management with a total amount of 39,043.06 million RMB, with an outstanding balance of 30,023.13 million RMB[142] - The company has no overdue amounts in its entrusted financial management[142] - The company has not provided guarantees for shareholders, actual controllers, or related parties[140] Corporate Governance and Compliance - The company received a warning and fines totaling CNY 300,000 from the China Securities Regulatory Commission due to violations of information disclosure regulations[134] - The company has not faced any risks of suspension or termination of listing during the reporting period[132] - The company has fully resolved the issues related to the occupation of funds and pledged deposits by controlling shareholders as of June 29, 2020[128] - The company engaged Xinyong Zhonghe Accounting Firm for auditing services, with a remuneration of 65,000 RMB for the year[131] - The company appointed ShineWing Certified Public Accountants as the financial and internal control audit institution for the year 2020[132] Social Responsibility and Environmental Management - The company donated 30,000 RMB to support poverty alleviation efforts in the rural area of Shaanxi Province, specifically targeting the Niuyanghe Village in Shiquan County[156] - The company has established a volunteer team to engage in various charitable activities, emphasizing its commitment to social welfare and community support[162] - The company has implemented a comprehensive environmental management system, ensuring compliance with pollution discharge standards and maintaining good operational conditions for its environmental facilities[164] - In 2020, the company reported a wastewater discharge with a CODcr concentration of 16 mg/L, which is compliant with the relevant discharge standards[166] - The company has developed an emergency response plan for environmental incidents, which has been reviewed and filed with the local environmental authority[167] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,622, an increase from 19,054 at the end of the previous month[171] - The largest shareholder, Jinhua Investment Holding Group Co., Ltd., held 71,447,654 shares, representing 19.14% of total shares, with a decrease of 43,450,000 shares during the reporting period[173] - The second-largest shareholder, Xing Boyue, held 60,147,752 shares, accounting for 16.11% of total shares[173] - The company has no changes in the total number of ordinary shares and share capital structure during the reporting period[170] - The company reported no other significant events or changes related to its shareholders or controlling entities[180] Employee Management and Training - The company employed a total of 676 staff, with 498 in the parent company and 178 in major subsidiaries[195] - The company has established a training plan for 2020 aimed at enhancing management efficiency and quality management systems[197] - The training program includes middle management team development to improve management awareness and tool usage capabilities[197] - The company emphasizes the importance of internal training, with at least 70% of training conducted by management and technical staff[198] - The training materials will cover job responsibilities, operational standards, and emergency measures for each position[200]

金花企业（集团）股份有限公司 2021 年第一季度报告 1 / 19 2021 年第一季度报告 公司代码：600080 公司简称：ST 金花 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 8 | 2021 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | | --- | --- | --- | --- | --- | | | | | 减(%) | | | 总资产 | 1,907,798,227.68 | 1,958,574,300.85 | | -2.59 | | 归属于上市公司 | 1,729,011,737.03 | 1,721,338,898.70 | | 0.45 | | 股东的净资产 | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | | 经营活动产生的 | -37,984,546.27 | -14,582,174.05 | | 不适用 | | 现金流量净 ...

2020 年第三季度报告 公司代码：600080 公司简称：ST 金花 金花企业（集团）股份有限公司 2020 年第三季度报告 1 / 25 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人张朝阳、主管会计工作负责人孙明及会计机构负责人（会计主管人员）巨亚娟保 证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 5 | | 四、 | 附录 | 8 | 2020 年第三季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 3 / 25 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 1,962,746,918.76 1,979,851,640.25 -0.86 归属于上市公司 股东的净资 ...

Financial Performance - The company's operating revenue for the first half of 2020 was ¥260,131,661.79, a decrease of 24.84% compared to ¥346,125,198.01 in the same period last year[19] - The net profit attributable to shareholders for the first half of 2020 was ¥14,418,755.84, down 39.96% from ¥24,013,415.69 in the previous year[19] - The net cash flow from operating activities was negative at -¥24,435,333.25, compared to a positive cash flow of ¥11,524,390.87 in the same period last year[19] - The basic earnings per share for the first half of 2020 were ¥0.0386, a decline of 39.97% from ¥0.0643 in the same period last year[20] - The weighted average return on net assets decreased to 0.8399%, down 0.5066 percentage points from 1.3465% in the previous year[20] - The company achieved operating revenue of CNY 260.13 million, a decrease of 24.84% compared to the same period last year[40] - The net profit attributable to shareholders was CNY 14.42 million, down 39.96% year-on-year, with a net profit of CNY 8.07 million after deducting non-recurring gains and losses, a decrease of 59.68%[40] - The company reported a net profit margin improvement, with retained earnings rising from ¥479,907,264.27 to ¥483,127,911.56, an increase of about 0.5%[96] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,951,454,175.48, a decrease of 1.43% from ¥1,979,851,640.25 at the end of the previous year[19] - The total liabilities as of June 30, 2020, were not explicitly stated but are essential for assessing the company's financial health[93] - The total assets of the company reached CNY 1,781,101,834.25, demonstrating growth in the asset base[134] - The total liabilities of the company were reported at CNY 1,771,470,371.94, which is a critical factor in assessing financial health[136] - The total equity at the end of the reporting period is CNY 1,778,376,825.01, showing an increase from the previous period's CNY 1,771,677,937.61[140] Cash Flow - Cash and cash equivalents increased by 61.65% to CNY 482.27 million, primarily due to the repayment of funds occupied by the controlling shareholder[44] - The net cash flow from investment activities was 210,073,527.84 RMB, a substantial increase from 11,092,205.74 RMB in the previous half-year, showcasing improved investment performance[112] - The total cash inflow from operating activities was 299,840,409.11 RMB, down from 379,410,100.97 RMB, reflecting a decline in operational cash generation[111] - The cash outflow for purchasing goods and services was 56,178,082.91 RMB, compared to 77,075,305.30 RMB previously, indicating cost control measures[111] Research and Development - Research and development expenses increased by 84.54% to CNY 3.11 million, indicating a focus on innovation despite overall revenue decline[42] - The company has increased its R&D investment to develop related products in the orthopedic field, enhancing its core competitiveness[31] - The company is focusing on accelerating the progress of existing projects and enhancing R&D investment to mitigate new product development risks[51] Market and Industry - The company operates mainly in the northwest regions of China, including Shaanxi, Gansu, and Qinghai[24] - In the first half of 2020, the pharmaceutical industry experienced a decline, with total revenue of 1,109.39 billion yuan, a decrease of 2.3% year-on-year[27] - The company reported a total profit of 158.6 billion yuan in the pharmaceutical industry, which represents a year-on-year increase of 2.1%[27] - The new drug management law and healthcare reform policies are expected to promote healthy development in the pharmaceutical industry over the next decade[28] Quality Management - The company has maintained strict quality management throughout the production process, ensuring compliance with GMP standards and achieving stable product quality[34] - The company has implemented strict quality control measures, adhering to GMP requirements to ensure product safety[52] - The company is committed to maintaining product quality and has established a comprehensive quality management system to mitigate risks[50] Corporate Governance - The company did not distribute profits or increase capital reserves during the reporting period[6] - The company has resolved all issues related to the controlling shareholder's non-operating fund occupation and guarantees[39] - The company is actively improving internal control systems to prevent similar incidents of fund occupation in the future[39] - The company faced a fine of 300,000 yuan from the China Securities Regulatory Commission for information disclosure violations[60] Environmental Compliance - The company has maintained compliance with environmental standards, with no major environmental issues reported during the reporting period[74] - The nitrogen oxide emission concentration from the natural gas boiler is 26.67 mg/m3, complying with the standard of less than 30 mg/m3 for new gas boilers[76] - The company has established a comprehensive environmental monitoring plan, with third-party assessments confirming that all monitored pollutants are within compliance limits[76] Shareholder Information - The total number of shares and the capital structure of the company remained unchanged during the reporting period[80] - The top ten shareholders include Jinhua Investment Holding Group Co., Ltd. with 114,897,654 shares, accounting for 30.78% of total shares[84] - The company has not reported any changes in major shareholders or actual controllers, indicating stability in ownership[87] Strategic Initiatives - The company aims to expand its market presence by optimizing its distributor network and controlling distribution prices[36] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[136] - The company has implemented an employee stock ownership plan, with 1,076,759 shares allocated to employees, which may enhance employee engagement and retention[86]